Oncology Liquid biopsy and the future of tumour-agnostic treatments Liquid biopsy-based tools are positioned as a critical enabler of tumour-agnostic therapeutic development.
Oncology ESMO 2025 commences: ADCs, AI, and Asia ESMO 2025 has kicked off, with an opening press conference focused on early setting ADCs, the potential of AI in oncology, and new drugs from Asia.
News RNAi biotech City hauls in $200m in upsized IPO City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.